Semaglutide: A Gut-Hormone Mimic That Turns Down the Volume on Hunger

The short version

Semaglutide is a lab-made peptide that copies the structure of a natural gut hormone called GLP-1 — a signal the intestine releases after eating to tell the pancreas and brain that food has arrived. Because it is built to resist being broken down quickly, one injection lasts about a week instead of the few minutes the natural hormone lasts.

Semaglutide is an FDA-approved prescription medicine, not a research-only compound. It is approved for type 2 diabetes, for chronic weight management, for reducing serious heart events in people with existing heart disease, and, since 2025, for a form of liver disease linked to metabolic problems. Large trials involving tens of thousands of people back these approvals. The tradeoff, covered fully below, is a well-documented pattern of digestive side effects, especially early in treatment.

What it is

Semaglutide is a 31-amino-acid peptide built on the backbone of human GLP-1, sharing about 94% of the same sequence. Two small substitutions make the difference: one swap blocks an enzyme (DPP-4) that would otherwise break the molecule down within minutes, and a second swap improves its stability further. A fatty acid chain is then attached to one point on the molecule, which causes it to bind strongly — but reversibly — to albumin, the most abundant protein in blood. That binding acts like a slow-release anchor, shielding the peptide from being filtered out by the kidneys and stretching its effective lifespan to about a week, which is why it can be dosed once weekly instead of multiple times a day. An oral tablet version also exists, though very little of an oral dose is actually absorbed, so it has to be taken carefully, on an empty stomach, separate from food and other medication.

How it works

Semaglutide binds to GLP-1 receptors throughout the body. In the pancreas, it boosts insulin release only when blood sugar is already elevated, and dials down glucagon (a hormone that raises blood sugar) — a "glucose-dependent" design that limits the risk of blood sugar dropping too low when it is used on its own. It also slows how quickly the stomach empties, which extends the feeling of fullness after a meal and contributes to the nausea some people experience.

Its effect on appetite, though, is mostly happening in the brain, not the stomach. Semaglutide reaches appetite-control centers in the hypothalamus and brainstem, where it switches on neurons that signal fullness and switches down neurons that drive hunger. People often describe this as a quieting of constant background thoughts about food — sometimes called "food noise" — rather than simply feeling stuffed after eating.

What the research shows

Head-to-head against a newer dual-agonist. In the SURMOUNT-5 trial, 751 adults with obesity were randomized to either tirzepatide or semaglutide at each drug's best-tolerated dose. After 72 weeks, semaglutide produced about 13.7% average weight loss compared with 20.2% for tirzepatide — a statistically significant gap that positions semaglutide as the established benchmark a newer compound has since outperformed ^[13].

Kidney protection in diabetes (FLOW). In 3,533 adults with type 2 diabetes and chronic kidney disease, once-weekly semaglutide lowered the risk of major kidney-disease events — kidney failure, a large drop in kidney function, or kidney- or heart-related death — by 24% compared with placebo ^[14].

Heart protection without diabetes (SELECT). In 17,604 adults with existing heart disease and overweight or obesity but no diabetes, semaglutide reduced the combined risk of heart-related death, non-fatal heart attack, or non-fatal stroke by 20% compared with placebo ^[15].

Weight loss (STEP 1). In 1,961 adults with overweight or obesity and no diabetes, 68 weeks of once-weekly semaglutide produced an average 14.9% body-weight reduction, compared with 2.4% for placebo ^[16].

Overall safety picture. A dedicated safety review describes semaglutide's risk-benefit balance as favorable overall, with digestive side effects — nausea in roughly a third of people — as the dominant issue, alongside an increased risk of gallstones and cancer signals (pancreatic and thyroid) that remain too rare to draw firm conclusions from either way ^[17].

Reported effects, cautions & safety

The patterns below are anecdotal, not clinical evidence — drawn from public patient-review sites and community discussion rather than controlled studies, and none of them list a specific dose.

Reported benefits: By far the most common thing people describe is that constant background thinking about food goes quiet, often within the first week or two, alongside eating noticeably smaller portions without feeling deprived. Reduced cravings for sugar and fried food come up often, sometimes alongside a new preference for lighter meals. Steady weight loss over months is close to universal in these reports, and people managing type 2 diabetes frequently describe markedly better blood-sugar readings. A less expected but frequently mentioned effect is reduced interest in drinking alcohol.

Reported adverse effects: Nausea, sometimes escalating to vomiting, is the single most-reported side effect, typically worst in the first weeks and after each dose increase. Distinctive sulfur-smelling burps, bloating, and disrupted bowel habits (constipation, diarrhea, or both) are common complaints. Acid reflux, early fatigue on injection days, headaches, food aversions, and mild injection-site irritation are also frequently described, and a smaller group reports hair shedding tied to the pace of their weight loss rather than to the drug directly.

Cited cautions:

• Digestive intolerance during dose increases is the leading side effect in trials and the main reason people stop treatment; it is usually mild to moderate and temporary ^[17].
• A boxed warning for thyroid tumors exists because of findings in rodent studies; a clear link in humans has not been established, but a personal or family history of certain thyroid cancers is treated as a reason to avoid this drug ^[17].
• Pancreatitis is a recognized class-wide warning; treatment is generally stopped if it is suspected, though cancer-specific signals remain too rare to draw firm conclusions from ^[17].
• Gallbladder and gallstone risk is increased compared with placebo, attributed mostly to how fast and how much weight is lost rather than a direct drug effect ^[17].
• Retinopathy risk was higher in one major trial among people who already had diabetic eye disease and whose blood sugar dropped quickly — monitoring is advised when blood sugar is corrected rapidly ^[17].
• Loss of lean muscle mass alongside fat has been documented in body-composition sub-studies, raising a concern especially relevant to older adults.
• Weight tends to return after stopping, which is why this class of drug is generally framed as an ongoing therapy rather than a short course with a lasting cure.
• Pregnancy is a contraindication, and because the drug clears the body slowly, guidance calls for stopping it well ahead of a planned pregnancy.
• The oral tablet must be taken on a genuinely empty stomach, separate from food, drink, and other medication, or very little of the dose is actually absorbed.

Where it fits in Research Peptide Fundamentals

Semaglutide sits at the most thoroughly proven end of this guide, alongside Tesamorelin — both are FDA-approved medicines with large human trial programs behind them, in contrast to the research-chemical status of Ipamorelin and the supplement middle-ground of NAD+. What makes Semaglutide worth reading closely inside a "fundamentals" guide is precisely that it has already been surpassed head-to-head by a newer dual-receptor compound — a live example of how quickly this field moves, and why the evidence for any single compound is worth checking against what has come since. See the comparison page for the full picture across all four.